Skip Nav Destination
            
    
            
 
    
    
        
            
                
                
                    
                    
                        
                    
                
                
                    
                        
                        
                            
                        
                    
            
        
    
    
    
        
        
        
    
        
        
    
        
 
    
 
    
        
    
    
        
            
        
        
    
        
    
    
    
 
    
                
                    
            
    
        
    
    
                    
        
        
     
    
                     
    
                    
                    
                
            
    
    
    
        
        
     
    
                    
        
                    
        
        A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma
        
        
            
        
    
        
                
            
    
    
    
        
                    
        
        Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL
        
        
            
        
    
        
                
            
    
    
    
        
        
     
    
                     
    
                     
    
                    
        
                    
                
            
    
    
    
        
                    
                
            
    
    
        
    
        
                    
        
        Circulating tumor DNA determinants of response and outcome in relapsed/refractory mantle cell lymphoma
        
        
            
        
    
        
                
            
    
    
        
    
        
        
     
    
                     
    
                    
        
                    
                
            
    
    
    
        
        
     
    
                     
    
                     
    
                     
    
                    
        
                    
                
            
    
    
        
    
        
        
     
    
                    
        
        
                    
                
            
    
    
    
                    
        
        The efficacy of rosuvastatin to reduce circulating tissue factor extracellular vesicles after ovarian cancer surgery
        
        
            
        
    
        
                
            
    
    
    
        
        
     
    
                     
    
 
    
            
    
        
    
         
 
    
    
        
    
            
    
        
    
    
    
        
    
    
    
            
    
                    
 
    
    
 
    
    
    
        
    
    
    
            
        
            
    
        
        
    
             
            
             
            
             
        
    
 
    
    
 
    
    
        
    
    
    
            
    
                    
 
    
    
 
    
    
 
    
    
    
    
        
    Issue Archive
September 9 2025
    
    In this Issue
    
    Table of Contents
INSIDE BLOOD ADVANCES
ADVANCES VIEWPOINT
REVIEW ARTICLE
Up-front alternative donor HCT in severe aplastic anemia: gaps and opportunities to translate evidence into practice
            Neel S. Bhatt,Azra Borogovac,Yvonne A. Efebera,Anna DeSalvo,Steven M. Devine,Amy Foley,Valerie Greco-Stewart,Betty K. Hamilton,Mykala Heuer,Todd Molfenter,John P. Plastaras,Brittany K. Ragon,Sarah A. Wall,Larisa Broglie,Mark B. Juckett,Nandita Khera,Mary M. Horowitz,Amy E. DeZern
            
        
    
            CLINICAL TRIALS AND OBSERVATIONS
        
        A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma
        
        
            
        
                    
                        Clinical Trials & Observations
                    
        
            
    
        
            Neha Akkad,Lei Feng,Jason R. Westin,Fredrick B. Hagemeister,Hun Ju Lee,Luis Fayad,Sairah Ahmed,Ranjit Nair,Maria Alma Rodriguez,Paolo Strati,Dai Chihara,Christopher R. Flowers,Linda Claret,Karina Ibanez,Michael Wang,Nathan H. Fowler,Jared Henderson,R. Eric Davis,Sattva S. Neelapu,Michael Green,Loretta J. Nastoupil
            
        
    
            
        
        Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL
        
        
            
        
                    
                        Clinical Trials & Observations
                    
        
            
    
        
            Rakesh Awasthi,Stephan A. Grupp,Edward R. Waldron,Gregory A. Yanik,Constantine S. Tam,Susana Rives,Joseph P. McGuirk,Michael A. Pulsipher,Ulrich Jaeger,Gary D. Myers,Peter Borchmann,Stephen J. Schuster,Heather E. Stefanski,Michael R. Bishop,Abhijit Chakraborty,Aisha Masood,André Baruchel,Edmund K. Waller
            
        
    
            HEALTH SERVICES AND OUTCOMES
HEMATOPOIESIS AND STEM CELLS
LYMPHOID NEOPLASIA
BRCA1/2 impact on the development of implant-associated lymphoma in women with breast cancer and textured implants
            Paola Ghione,Diana Mandelker,Maria Arcila,Venkatraman Seshan,Mary Beth Terry,Joseph Vijai,Peter Cordeiro,Chad Vanderbilt,Joyce Pressley,Alexander Chan,Natasha Galasso,Ahmet Dogan,Gilles Salles,Daphne de Jong,Flora van Leeuwen,Steven Horwitz
            
        
    
            The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in patients with lymphoma
            Adi Zoref-Lorenz,Jun Murakami,Ronit Gurion,Swaminathan P. Iyer,Uri Abadi,Inbar Cohen,Gaurav Goyal,Shehab Mohamed,Sarah Nikiforow,Abd El Haleem Natour,Shiri Weinstein,Joanne Yacobovich,Hae Lin Cho,Pia Raanani,Arnon Nagler,Nancy Berliner,Naval Daver,Gilad Itchaki,Shai Izraeli,Martin Ellis,Michael B. Jordan
            
        
    
            
        
        Circulating tumor DNA determinants of response and outcome in relapsed/refractory mantle cell lymphoma
        
        
            
        
                    
                        Clinical Trials & Observations
                    
        
            
    
        
            Leo Meriranta,Rasmus Rask Kragh Jørgensen,Annika Pasanen,Arne Kolstad,Martin Hutchings,Carsten Utoft Niemann,Tarec Christoffer El-Galaly,Jon Riise,Jacob Haaber Christensen,Kristina Sonnevi,Lone Bredo Pedersen,Karin Fahl Wader,Ingrid Glimelius,Sirpa Leppä,Mats Jerkeman
            
        
    
            MYELOID NEOPLASIA
PLASMA CELL DISORDERS
Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging
            Carolina Schinke,Leo Rasche,Cody Ashby,Rudy van Hemert,Sharmilan Thanendrarajan,Samer Al Hadidi,Maurizio Zangari,Clyde Bailey,Daisy V. Alapat,John D. Shaughnessy, Jr,Fenghuang Zhan,Bart Barlogie,Frits van Rhee,Niels Weinhold
            
        
    
            PLATELETS AND THROMBOPOIESIS
RED CELLS, IRON, AND ERYTHROPOIESIS
TRANSFUSION MEDICINE
TRANSPLANTATION
Impact of shared HLA determinants between patient and losing cord blood unit on relapse after double cord blood transplantation
            Robert Wynn,Fernanda Volt,Philippe Guardiola,Srividhya Senthil,Graziana Scigliuolo,Chantal Kenzey,Barbara Cappelli,Annalisa Ruggeri,Ryad Tamouza,Vanderson Rocha,Chloe Anthias,Régis Peffault de la Tour,Katherine Clesham,Anna Castleton,Michel Schaap,Persis Amrolia,Marc Bierings,Jan J. Cornelissen,Kay Poulton,Eliane Gluckman
            
        
    
            RESEARCH LETTERS
Patterns of progression among 427 patients with smoldering myeloma diagnosed after 2014: importance of monitoring
            Efstathios Kastritis,Irene Solia,Panagiotis Malandrakis,Foteini Theodorakakou,Ioannis Ntanasis-Stathopoulos,Nikolaos Kanellias,Despina Fotiou,Magdalini Migkou,Evangelos Eleutherakis-Papaiakovou,Vassiliki Spiliopoulou,Nikoleta Kokkali,Asimina Papanikolaou,Stavroula Giannouli,Maria Gavriatopoulou,Evangelos Terpos,Meletios A. Dimopoulos
            
        
    
            
        
        The efficacy of rosuvastatin to reduce circulating tissue factor extracellular vesicles after ovarian cancer surgery
        
        
            
        
                    
                        Clinical Trials & Observations
                    
        
            
    
        
            Soravis Osataphan,Rushad Patell,Mrigya Babuta,Rachel P. Rosovsky,Yohei Hisada,Charly Edmiston,Pavania Elavalakanar,Michael A. Pfeffer,Amy Bregar,Amanda Ramos,Leslie Garrett,Siyang Ren,Donna Neuberg,Gyongyi Szabo,Robert Flaumenhaft,Nigel Mackman,Meghan Shea,Jeffrey I. Zwicker
            
        
    
            COMMENTARY
- 
        
            Cover Image
        
        Cover Image![issue cover]()  Illustration of the roles of PROSER1 and TET2 in the regulation of DNA methylation and hematopoiesis. PROSER1 is a pan-TET interactor important for maintenance of DNA methylation homeostasis in hematopoietic cells. Loss of PROSER1 results in disruption of TOPD (TET-OGT-PROSER1-DBHS) complexes and overlapping and distinct enhancer DNA methylation changes compared to changes observed in TET2 knockout cells. These DNA methylation changes and the resulting deregulation of genes governing cell cycle and hematopoietic stem cells (HSCs) likely drive the observed exhaustion of HSC activity over time. See the article by Knatko et al. 
Advertisement intended for health care professionals
Advertisement intended for health care professionals
 
                    















 
            
Reality bites: allocating gene therapy for hemoglobinopathies